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Thomas O. Mason,[c] Ulyana Shimanovich,[c] Tuomas P. J. Knowles,[c] Andrew T. Smith,[d]
Elizabeth B. Sawyer,*[a] and Sarah Perrett*[a, c]
Introduction
Amyloid fibrils are stable, highly ordered polypeptide aggre-
gates, the assembly of which can be controlled in vitro by al-
tering conditions such as temperature, degree of agitation,
and the presence of cosolvents. Several diseases are associated
with the accumulation of amyloid fibrils,[1] yet examples of
amyloid fibrils that occur naturally with positive biological
functions have also been identified recently, which include
the curli proteins of Escherichia coli and Ure2 of Saccharomyces
cerevisiae.[2] Fibril morphology and structure are affected by
the assembly conditions and the presence, position, and con-
formation of molecules appended to the amyloidogenic
domain.[3] The extraordinary stability and tunable assembly of
amyloid fibrils make them attractive targets as nanomaterials ;[4]
indeed, the functionalization of amyloid fibrils by metal
binding and cytochrome display has already been explored[5]
and significant signal enhancements have been demonstrated
if amyloid fibrils are employed in immuno- or biosensor as-
says.[6]
Ure2 is a regulator of nitrogen metabolism in S. cerevisiae
through its conformation-dependent interactions with the
transcription factor Gln3. The fibrillar form of Ure2 propagates
in a manner analogous to mammalian prions,[2b] which makes
it a useful tool to enhance the understanding of prions in gen-
eral. Although no high-resolution structural data have yet
been obtained, several recent structural studies on Ure2 fibrils
have proposed the following model: the N-terminal prion
domain (residues 1–93), which is rich in Asn and Gln residues
and is necessary and sufficient for fibril formation in vitro and
prion propagation in vivo[7] forms a cross-b fibril core, around
which the C-terminal globular domains are displayed.[8] The C-
terminal domain (CTD), a structural homologue of glutathione
transferase enzymes,[9] forms a homodimer and shows gluta-
Enzyme immobilization is an important strategy to enhance
the stability and recoverability of enzymes and to facilitate the
separation of enzymes from reaction products. However,
enzyme purification followed by separate chemical steps to
allow immobilization on a solid support reduces the efficiency
and yield of the active enzyme. Here we describe polypeptide
constructs that self-assemble spontaneously into nanofibrils
with fused active enzyme subunits displayed on the amyloid
fibril surface. We measured the steady-state kinetic parameters
for the appended enzymes in situ within fibrils and compare
these with the identical protein constructs in solution. Finally,
we demonstrated that the fibrils can be recycled and reused in
functional assays both in conventional batch processes and in
a continuous-flow microreactor.
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thione peroxidase and glutaredoxin activities in both the solu-
ble and fibrillar forms of the protein.[10]
The central core of the Ure2 fibril is formed from the first
80 residues.[8b] Residues 81–100 provide flexibility between the
prion domain and the CTD; this is important for the amyloid
formation of Ure2[11] and also offers the possibility of replacing
the CTD with other proteins.[8a] Although the appendage of
globular proteins to some amyloidogenic peptides requires
that the globular protein first unfolds for fibrils to form,[12] the
globular C domain of Ure2 is accommodated in its native state
within the fibrils.[8a,10]
The value and use of commercial and industrial enzymes
can be enhanced by immobilization. A key advantage of this
process is the introduction of a phase separation between the
enzyme and the reaction mixture, which facilitates the recov-
ery and reuse of the enzyme and purification of the product.
Immobilization has relied traditionally on four strategies: ad-
sorption, covalent attachment of enzymes to carriers, entrap-
ment, and chemical cross-linking.[13] However, each of these
methods may reduce the proportion of conformationally active
enzyme, reduce flexibility, or limit the access of the substrate
to the enzyme. Although some nanostructures, such as nano-
particles, nanofibers, and mesoporous silica, have been tested
as immobilization materials to improve the surface-area-to-
volume ratio, limitations in terms of dispersion in solution,
a substrate diffusion barrier, efficiency of enzyme immobiliza-
tion, and ability to recycle still remain.[14] Thus, there is a signifi-
cant driving force for the development of alternative methods
for enzyme immobilization.
Several recent studies indicate a strong interest in the possi-
bility of using amyloid fibrils as a scaffold for the immobiliza-
tion of proteins of biological or chemical interest.[3b,4–6] Chemi-
cal cross-linking has been used to attach an enzyme to an
amyloid scaffold.[4b] However, the cross-linking approach is in-
evitably hard to control and leads to heterogeneity of the
system and potential modification of the molecule of interest.
In contrast, the genetic fusion approach applied here leads to
highly efficient and homogenous self-assembly. Previous stud-
ies have used the prion domain of another yeast prion protein,
Sup35, as the fibril-forming component of a fusion protein
nanowire that comprises monomeric proteins that fold reliably
when overexpressed.[6] Likewise, an earlier study indicated the
potential of the Ure2 prion domain to form fibrils containing
appended enzymes, at least for proteins that are expressed
and folded easily.[8a] In contrast, we have explored the possibili-
ty of using the Ure2 prion domain to display enzymes with
specific folding requirements and diverse architectures and we
have chosen alkaline phosphatase (AP) and horseradish perox-
idase (HRP) as industrially important enzyme models. We ex-
ploit the homogeneity of the system to perform quantitative
characterization of enzymatic parameters for both soluble and
fibrillar forms of the genetically fused constructs. Finally, we
demonstrate the practical application of the enzymatically
active fibrils to immobilize and, thereby, recycle and reuse the
enzymes in both traditional batch processes and as the basis
for flow chemistry in microfluidic channels.
Results and Discussion
Chimeric AP and HRP form fibrils with the cross-b architec-
ture characteristic of amyloid
The prion domain of Ure2 was attached to the N terminus of
AP or HRP, both of which have widespread applications in clini-
cal and immunodiagnostic use and can be assessed for activity
using simple colorimetric, fluorescent, or luminescent assays
even at low (single molecule) concentrations, which raises the
possibility of using our chimeras to probe the assembly and
subunit structure of Ure2. AP assembles as a mirror symmetric
dimer (unlike the wild-type (WT) Ure2 dimer, which has axial
symmetry) and catalyzes the hydrolysis of mono- and diphos-
phoesters from a range of substrates. HRP is a monomeric he-
moglycoprotein enzyme capable of the very rapid turnover of
a range of synthetic substrates. It forms inclusion bodies if
overexpressed in E. coli and requires refolding in vitro (which
includes the formation of four disulfide bonds and the incorpo-
ration of one heme cofactor and two Ca2+ ions) to achieve its
active conformation[15] (see Supporting Information).
Figure 1. Chimeras between the Ure2 prion domain and AP or HRP enzymes
form amyloid fibrils. A) Upper panel : negative-staining TEM of WT Ure2 and
chimeric fibrillar aggregates. All scale bars 200 nm. Lower panel: widths of
Ure2 and chimeric fibrils measured from TEM images. WT Ure2, Ure2193-AP,
and Ure2193-HRP show median widths of 19, 26, and 23 nm (n>300), re-
spectively, consistent with their relative molecular weights. Ure2180-HRP fi-
brils have a smaller diameter than HRP chimeric fibrils that contain the full-
length prion domain of Ure2 (residues 1–93). CD spectra of native (open
squares) and fibrillar (closed circles) B) Ure2193-AP and C) Ure2180-HRP. Fibril
assembly of chimeric proteins is associated with an increase in b-sheet con-
tent. X-ray fiber diffraction patterns of D) Ure2193-AP fibrils and E) Ure2180-
HRP fibrils, which show anisotropic reflections at 4.7 and 10 .
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All the chimeric proteins formed fibrillar aggregates, which
were characterized by negative-staining TEM, circular dichro-
ism (CD) spectroscopy, and X-ray fiber diffraction (Figure 1).
The fibril morphologies were similar to that of WT Ure2 and
their widths were consistent with the relative monomeric mo-
lecular weights of the soluble proteins (WT Ure2 CTD,
29.8 kDa; AP, 49.4 kDa; HRP, 34.0 kDa). CD spectroscopy re-
vealed a significant increase in the proportion of b-sheet sec-
ondary structure after fibril formation, consistent with the as-
sembly of proteins into cross-b amyloid fibrils (Figure 1B and
C), and X-ray fiber diffraction of dry stalks gave rise to aniso-
tropic reflections at 4.7 and 10  for Ure2193-AP and Ure2180-
HRP fibrils, respectively, characteristic of the presence of
a cross-b fibril core[16] (Figure 1D and E) similar to that of WT
Ure2.[8d,17]
AP and HRP chimeric fibrils show enzymatic activity: Insight
into the effects of enzyme immobilization from steady-state
kinetic parameters
Similar to WT Ure2,[10] our chimeras retained their enzyme ac-
tivities after fibril formation. Activities were measured for both
soluble and fibrillar samples at a range of substrate concentra-
tions, and the steady-state enzyme kinetics data for the chime-
ras were compared to those of WT AP and WT HRP. The sub-
strates used were p-nitrophenyl phosphate (pNPP) and 2,2’-azi-
nobis-(3-ethylbenzthioazoline-6-sulfonic acid) diammonium salt
(ABTS) for AP and HRP, respectively. The kinetic parameters ob-
tained are shown in Table 1. Attachment of the Ure2 prion
domain to the N terminus of AP appeared to lower the affinity
of the enzyme for the substrate after the formation of amyloid
fibrils, as suggested by an increase in the apparent Michaelis
constant (KM), whereas the soluble chimera showed a more
similar KM value to that of WT AP. Soluble and fibrillar forms of
Ure2193-AP showed similar catalytic activities, around 10-fold
lower than that of WT AP, as indicated by the turnover number
at saturation, kcat. This suggests that the observed reduction in
catalytic activity is a result of the addition of the fusion itself,
which may partially compromise the folded structure of AP.
However, within the fibrils, the native AP molecules are dis-
played in a manner that is readily accessible to the substrate
and catalyzes the phosphatase reaction with similar efficiency
to the soluble form of the same enzyme construct.
The full-length prion domain (residues 1–93) was fused to
the N terminus of HRP, but the activity of the resulting fibrils
was low. The shortening of the prion domain (using only resi-
dues 1–80, which has previously been shown to allow fibril for-
mation of the prion domain[8b]) led to an approximate dou-
bling of the catalytic activity for the fibrillar form. As a result of
the nature of the peroxidase reaction cycle (a ping pong
mechanism dominated by compulsory second-order steps[18]),
the apparent KM cannot be equated directly with substrate af-
finity. The ratio of kcat/KM is, however, a relative estimate of the
slowest second-order step k3 (the rate for substrate association,
which corresponds to the reduction of compound II to resting
enzyme[19]) in the catalytic cycle.[18] This parameter shows a dra-
matic decrease for the fibrillar form compared with the soluble
form. The most probable explanation for this is reduced
enzyme activity because of the steric hindrance of substrate
access to the aromatic donor binding site at the reactive heme
edge (centered on Phe 179 in WT HRP[18]). The more marked
effect on catalytic activity upon fibril formation for HRP com-
pared to AP is consistent with the very high turnover number
of HRP, which means that the rate of catalysis is essentially dif-
fusion controlled.
Chimeric fibrils of AP and HRP display a similar fibril core
structure to WT Ure2
The fibril core can be identified by its resistance to proteases.
We used proteinase K digestion and Western blotting to assess
the composition of the fibril cores of our chimeric protein fi-
brils. All fibrils were treated for at least 24 h with 0.5 mgmL1
proteinase K, a broad-spectrum serine protease that cleaves
next to aliphatic and aromatic residues, and the fibril cores
that remained were analyzed by TEM. Similar core widths (6–
8 nm) were observed for all samples (Figure 2A), and washed
pellets that contained only the fibril cores did not show any
enzymatic activity against the test substrates.
The composition of the fibril cores was also tested by West-
ern blot using an anti-Ure2 primary antibody. After proteinase
K digestion, the fibril cores were washed with buffer and dis-
solved in 8m urea with 2% sodium dodecyl sulfate
(SDS) for polyacrylamide gel electrophoresis (PAGE).
Protein bands that correspond to the fibril cores do
not stain efficiently with Coomassie Blue, but silver
staining revealed smeared bands around 13 kDa in
size, which correspond to the dissolved fibril core.
These bands showed immunospecificity to the anti-
Ure2 antibody, whereas degraded WT AP and HRP
(negative controls) were not recognized by the anti-
body (Figure 2B).
Further evidence that the chimeric proteins share
the same fibril core as WT Ure2 comes from cross-
seeding assays. The fibril formation of Ure2 and
Ure2193-AP was seeded with WT Ure2 and chimeric
protein fibril seeds and monitored by thioflavin T
(ThT) fluorescence. A decrease in the lag phase of WT
Table 1. Kinetic parameters kcat and KM derived from the analysis of the rate of reac-
tion of various AP and HRP constructs under steady-state conditions using pNPP and
ABTS as substrates, respectively.
Enzyme Construct kcat [s
1][a] KM [mm]
[a] kcat/KM [mm
1 s1][a]
AP WT AP 45.31.4 231 1.97
Ure2193-AP 3.30.1 355 0.09
Ure2193-AP (fibril) 4.00.3 9424 0.04
HRP WT HRP 59218 41222 1.44
Ure2180-HRP 21913 25825 0.85
Ure2193-HRP 15517 19739 0.79
Ure2180-HRP (fibril) 723 60451 0.12
Ure2193-HRP (fibril) 312 41036 0.08
[a] The errors shown are the standard error of the fit of the data shown in Figure S3
in the Supporting Information.
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Ure2 and Ure2193-AP fibril formation was observed after seed-
ing (Figure 3A and B).
The self-assembly of Ure2193-HRP and Ure2180-HRP was
monitored by TEM because fibril formation did not give rise to
any change in ThT fluorescence, perhaps because of quench-
ing by HRP-bound heme. Large fibrils were observed after
seeding, whereas no fibrils were observed in the nonseeded
samples (Figure S1A and B in the Supporting Information). All
fibril seeds appeared as short rods in the TEM images, and no
change was observed after 3 h incubation under the condi-
tions of the seeding assay in the absence of soluble protein
(Figure S1C in the Supporting Information). WT Ure2 and Ure2
chimeras were able to cross-seed each other’s growth, which
suggests that the stacking within these fibrils (i.e. , the struc-
ture of the fibril core) is similar. This is consistent with a model
in which the fibril cores are formed of the prion domain of
Ure2, and AP/HRP is displayed on the surface, which has been
suggested previously for fibrils of WT Ure2.[8]
Chimeric fibrils can be recycled in functional assays in both
batch processes and in a continuous-flow microreactor
One of the primary goals of enzyme immobilization is the abili-
ty to recover and reuse enzymes. This is significant economi-
cally but also facilitates subsequent purification of the product
by the full removal of one component of the reaction mixture
in bulk. Our chimeric fibrils could, for instance, be reacted with
substrate repeatedly, recovered by centrifugation, washed, and
then recycled with minimal loss of yield or activity after each
round of reaction and recycling (Figure S2 in the Supporting
Information).
In addition to enzyme recovery through batch processes
such as centrifugation, the availability of the enzymatically
functionalized nanoscaffold architecture developed in this
study also opens up the possibility of using flow chemistry to
perform reactions under continuous-flow conditions in which
the separation of the active enzymes from the reaction prod-
Figure 3. Cross-seeding of chimeric fibrils and WT Ure2 monitored by ThT
fluorescence. A) WT Ure2 and B) Ure2193-AP each seeded with WT Ure2 or
chimeric fibril seeds as indicated. The lag phases of WT Ure2 and Ure2193-
AP fibril formation were reduced by seeding. (Errors shown are the standard
error of the mean of three measurements. See Figure S1 in the Supporting
Information.)
Figure 2. Chimeric fibrils of AP and HRP display a similar fibril core structure
as WT Ure2. A) Negative-staining TEM images of WT Ure2 and chimeric pro-
tein fibrils after proteinase K (PK) digestion. All scale bars 200 nm. B) Anti-
Ure2 Western blot (lower panel) of insoluble pellets of WT Ure2 and chimeric
protein fibrils with or without PK digestion, centrifuged and washed with
buffer three times, and dissolved in 8m urea prior to SDS-PAGE (upper
panel). The similarity in widths and morphologies of the fibril cores, and im-
munospecificity to Ure2 antibody of digested chimeric fibrils, suggests that
the chimeric fibrils and WT Ure2 share a common fibril core.
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ucts occurs in a continuous manner. We demonstrated this
idea by packing chimeric fibrils into a microcolumn and found
that the substrate could be readily pumped in and the product
could be collected in the flow-through (Figure 4). The fibrils
could be washed repeatedly and reused with the same or dif-
ferent substrates. No cross-reactivity between substrates was
found after washing with buffer. This finding confirms that the
fibrils are stable in dilute solution and can be efficiently recy-
cled and reused. Furthermore, they can be readily applied in
microscale detection and high-throughput measurements.
To further confirm whether the level of activity retained in
our fibril-immobilized enzymes has any potential commercial
or industrial application, we tested the possibility of using
Ure2193-AP fibrils in place of shrimp alkaline phosphatase
(SAP). SAP is used routinely in molecular biology to remove 5’
phosphate groups from DNA to prevent self-ligation. After re-
action, it is necessary to remove or inactivate the SAP so that
the target DNA insert is not also dephosphorylated. This is nor-
mally achieved by irreversible heat inactivation of the enzyme
by incubation at 70 8C for 30 min. To test whether Ure2193-AP
fibrils are as effective as SAP at dephosphorylating DNA,
a blue/white selection assay was used. Top10 E. coli were trans-
formed with DNA that had been treated with buffer, SAP, or
Ure2193-AP fibrils before ligation, and the proportion of blue/
white colonies was determined. Blue colonies indicate the reli-
gation of the vector without gene insertion, whereas white col-
onies indicate successful gene insertion.
The immobilized AP was recycled and re-reacted with the
same linear plasmid (pUC19) to test its recyclability. Meanwhile,
another plasmid (pHSG299) with different antibiotic resistance
was used to check for plasmid contamination from the previ-
ous reaction when Ure2193-AP fibrils are reused. The results of
the screening assay are shown in Figure 5. Not only do
Ure2193-AP fibrils catalyze the phosphatase reaction as effi-
ciently as commercial SAP but they can also be recovered and
recycled with the same proportion of positive colonies and
without plasmid contamination from previous reactions. Fur-
thermore, the ability to separate Ure2193-AP fibrils easily from
the reaction mixture, and the lack of requirement for heat de-
naturation, means that immobilized AP is more convenient to
use than SAP. Thus, Ure2193-AP fibrils offer a sustainable and
cost-effective alternative to the use of SAP in molecular
biology.
Conclusions
In our system, the prion domain of Ure2 provides a naturally
stable linker between the fibril core and enzymatic domain
and allows the immobilization of the enzymes with high effi-
ciency and homogeneity. The tunable self-assembly of our
system, the ability to separate enzymes from substrate/product
by centrifugation or trapping within a column, and the excel-
lent recyclability of our enzymatic fibrils satisfy the require-
ments for efficient enzyme immobilization. The enzymes we
have chosen to append to the Ure2 prion domain demonstrate
Figure 4. Application of chimeric fibrils in a continuous-flow microreactor. Fi-
brils were trapped in a microcolumn, which allowed the substrate to be in-
troduced through continuous flow and the reaction product was collected
at the outlet. A) Diagram of the structure of the microcolumn (right panel)
indicated in the photograph by a red box (left panel). The microcolumn was
fabricated using soft lithography techniques into polydimethylsiloxane.[20]
B) Schematic of flow chemistry. C) Bright-field images of agarose interface
used to trap fibrils (Panel I), and stacking of the fibrils on the agarose inter-
face (Panel II). Panel III : bright-field image (left) and ThT fluorescence image
(right) of trapped fibrils. Weak intrinsic fluorescence of fibrils (right, inset).
Panel IV: colorless substrates were loaded into the column and colored
products were collected. See Experimental Section for further details.
Figure 5. Application of AP chimeric fibrils in a molecular biology assay. Plas-
mids (as indicated) treated with buffer (Con, control), SAP, Ure2193-AP fibrils
(F), or recycled Ure2193-AP fibrils (R-F) were transformed into Top10 cells for
blue/white selection. White colonies on the plates indicate successful phos-
phatase treatment and gene insertion. The proportion of white colonies
after treatment is represented in the graph. Ure2193-AP fibrils are at least as
effective as SAP but more convenient to use and can be recycled. Further-
more, for the pHSG299 plasmid treated with recycled Ure2193-AP fibrils, the
absence of any colonies growing on the Amp+ plate indicates that plasmid
contamination of reused Ure2193-AP fibrils is absent. See Experimental Sec-
tion for further details.
 2014 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemCatChem 2014, 6, 1961 – 1968 1965
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the capacity of this domain to support a variety of molecular
sizes and architectures. Alkaline phosphatase is nearly twice
the size of the Ure2 C-terminal domain and the arrangements
of the dimers are completely unalike. Horseradish peroxidase
(HRP) is a difficult protein to express in its native state from
E. coli, and refolding from inclusion bodies is required. As
a result of its varied and widespread commercial use, there is
interest in the production of a recyclable form of HRP. Finally,
we have demonstrated that the efficiency, stability, and homo-
geneity of our self-assembly system allows the direct compari-
son of enzyme kinetic parameters for the soluble and fibrillar
forms of the same protein construct, which provides insight
into the effects of immobilization and thus strategies for fur-
ther optimization and development. Thus, the prion domain of
Ure2 appears to be an ideal scaffold for the immobilization
and display of active enzymes on amyloid fibrils as well as
a new vehicle to understand fibril assembly.
Experimental Section
Materials
Unless otherwise stated, reagents were purchased from Sigma
(Sigma–Aldrich co. LLC), and solutions were made using water pu-
rified to a resistance of 18.2 MW (Millipore). Protein concentrations
were determined by absorbance at 280 nm using extinction coeffi-
cients of 48220 (WT Ure2), 33140 (AP constructs), or
13050m1 cm1 (HRP constructs; the prion domain of Ure2 con-
tains no Tyr, Trp, or Cys residues), or by bicinchoninic acid (BCA)
assay (Pierce Biotechnology Inc.) following the addition of 2% SDS
and incubation at RT for at least 1 h to dissolve fibrils.
Protein expression and purification
Standard molecular cloning techniques were used to fuse together
genes that encode the prion domain of Ure2 and AP (the E. coli K-
12 gene was kindly provided by Prof. Qun Wei, Beijing Normal Uni-
versity, China) or HRP (synthetic HRP isoenzyme C (HRP-C)[21]). WT
Ure2 and Ure2193-AP were cloned into a mini-pRSETa expression
vector (kindly provided by Dr. Mark Bycroft, MRC LMB) and ex-
pressed with an N-terminal 6x-His tag. WT HRP and all HRP chime-
ras were cloned into pET24a expression vectors for expression
without His tags.
WT Ure2, WT AP and Ure2193-AP were expressed in C41 E. coli in
2YT media. The cells were grown at 37 8C to an optical density
600 nm of 0.6, induced with 0.4 mm isopropyl b-d-1-thiogalacto-
pyranoside (IPTG) and grown at 16 8C for 20 h. The cells were har-
vested by centrifugation at 5000g for 50 min and resuspended in
buffer A (50 mm Tris-HCl, 150 mm NaCl, pH 8.0). Cells were then
lysed by using a high-pressure cell press (JNBIO JN-3000 PLUS),
and the insoluble material was removed by centrifugation at
30000g for 60 min. The soluble Ure2 and Ure2193-AP contained
in the supernatants were applied to nickel-affinity chromatography
resin (Chelating Sepharose Fast Flow, Amersham Biosciences) and
purified according to manufacturer’s guidelines. Imidazole was re-
moved from the purified proteins by buffer exchange into buffer A
by using Amicon centrifugal concentrators (Millipore). Soluble WT
AP was further purified by anion-exchange chromatography by
using a Q Sepharose Fast Flow column (Amersham Biosciences).
The purity of the proteins was estimated by SDS-PAGE to be
>95%.
WT HRP, Ure2193-HRP and Ure2180-HRP were expressed in BL21
E. coli at 16 8C in 2YT media after induction with 0.2 mm IPTG.
The cells were harvested by centrifugation at 5000g for 50 min
and resuspended in 50 mm Tris-HCl, 10 mm ethylenediaminetetra-
acetic acid (EDTA), and 1 mm 1,4-dithiothreitol (DTT), pH 8.0 buffer.
Following pressure lysis, WT HRP, Ure2193-HRP, and Ure2180-HRP
were purified and refolded from inclusion bodies using a modified
version of the method described previously.[21] In brief, the purified
WT HRP, Ure2193-HRP, and Ure2180-HRP inclusion bodies were dis-
solved in 8m Urea, 50 mm Tris-HCl, and 1 mm DTT, pH 8.0. The de-
natured proteins were refolded by stepwise dilution in 2m urea
that contained 50 mm Tris-HCl (pH 8.0), 8 mm CaCl2, and 0.7 mm
glutathione disulfide (GSSG). First, the inclusion body mixture
(100 mL) was added to an equal volume of refolding buffer, and
heme was added to a final concentration of 10 mm. After 30 min,
further folding buffer/inclusion body mixture (200 mL) was added
into the original, and the heme concentration was adjusted back
to 10 mm by further addition of stock solution. This was repeated
until the final volume of the mixture reached 1 L over a period of
approximately 17 h at 4 8C to a final protein concentration of
0.2 mgmL1. Heme precipitate was removed by centrifugation, and
the protein was concentrated by using an Amicon centrifugal con-
centrator (Millipore) to a final volume of 90–100 mL. The refolded
WT HRP, Ure2193-HRP, and Ure2180-HRP were then dialyzed against
buffer B (20 mm Na acetate, pH 4.3, that contained 1 mm CaCl2).
Again, the purity of the proteins estimated by SDS-PAGE was
>95%. A UV/Vis spectrum of the protein preparations showed
a five-coordinate high-spin spectrum typical of active peroxidase
with Reinheitszahl (RZ; a measure of the hemin content by the ab-
sorbance ratio A403/A275) values of >2.7.
Fibril formation
Ure2193-AP fibrils were formed by incubation at 4 8C for 2 days
without shaking. WT Ure2, Ure2193-HRP, and Ure2180-HRP fibrils
were formed by shaking at 220 rpm (Refrigerated Incubator Shaker,
Innova 4230, New Brunswick Scientific) at 30 8C. The protein con-
centrations used for fibril formation were typically 50–70 mm. Fibril
formation was monitored by ThT fluorescence as described previ-
ously[22] and/or the resulting fibrils were characterized by negative-
staining TEM. Conditions were chosen to allow the reproducible
formation of fibrils of consistent lengths and diameters and with-
out the loss of enzyme activity or the formation of amorphous
aggregates.
Electron microscopy
For negative-staining TEM, 6 mL drops of suspensions of fibrils or
soluble proteins (protein concentration around 30 mm) were
loaded onto glow-discharged carbon-coated grids for 1 min and
blotted with filter paper to remove extra sample, then rinsed with
deionized water (6 mL) and stained with 2% uranyl acetate for 20 s.
Micrographs were recorded by using a CM120-FEG (FEI) micro-
scope operating at 100 kV.
CD spectroscopy
CD spectra were obtained by using a Pistar-180 instrument at RT.
All spectra were measured using a 1 mm pathlength quartz cuv-
ette, 1 nm step size, and 2 nm slit width in buffer A for Ure2193-AP
and buffer B for Ure2180-HRP, using protein concentrations of 6
and 3 mm, respectively.
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X-ray fiber diffraction
Chimeric fibrils were washed with deionized water three times to
remove salts, then the washed fibrils were dried and aligned on
the end of a glass capillary, as described previously.[23] X-ray diffrac-
tion patterns of the dehydrated fibril stalks were collected by
using a Rigaku R-AXIS IV+ + image-plate system calibrated against
high-density polyethylene (HDPE). The sample–detector distance
was 250 mm and the exposure time was 30 s. The 2D diffraction
patterns were converted into tiff images by using fit-2D and inte-
grated into 1D scattering profiles by using Image J.[23]
Western blot
Protein fibrils were washed with buffer three times, resuspended in
buffer at concentrations of 40–70 mm, and incubated with
0.5 mgmL1 proteinase K (Amresco) and 1 mm CaCl2 for more than
24 h at 37 8C. Insoluble material was collected by centrifugation at
10000g for 15 min at 4 8C, washed twice with buffer, dissolved in
8m urea, and boiled in the presence of 2% SDS for SDS-PAGE. Pro-
teins in the gels were subjected to silver staining or transferred to
polyvinylidene difluoride (PVDF) membrane for Western blot. A
polyclonal anti-Ure2 antibody (made by Sino Biological Inc. , China)
was used to test the immunospecificity of the samples.
Cross-seeding assay
To generate seeds, fibrils were diluted to 2–3 mm and sonicated
(750 Watt Ultrasonic Processors, SONICS) at 30% power for 1 min
(1 s on and 1 s off) in Eppendorf tubes incubated on ice. The fibril
seeds diluted with buffer A were used to seed the fibril formation
of Ure2 and Ure2193-AP, and seeds diluted with buffer B were used
to seed Ure2193-HRP and Ure2180-HRP fibril formation. Solutions
of Ure2 and chimeric proteins (30–40 mm) contained 2–3% seeds
of Ure2 or Ure2193-AP, or 4% seeds of Ure2193-HRP or Ure2180-
HRP. For the Ure2-AP cross-seeding assays, Ure2 or Ure21–93-AP
(150 mL; soluble protein or seeds) was loaded into 96-well plates
and shaken at 30 8C. Fibril formation was monitored by ThT fluores-
cence (17 mm ThT) by using a plate-reader (SpectraMax M3 Multi-
Mode Microplate Reader, Molecular Devices). For Ure2193-HRP and
Ure2180-HRP, the seeding mixture was divided into 400 mL aliquots
and incubated at 30 8C with 220 rpm shaking (Refrigerated Incuba-
tor Shaker, Innova 4230, New Brunswick Scientific). Fibril formation
was monitored by negative-staining TEM (Ure2193-HRP and
Ure2180-HRP fibrils do not exhibit ThT fluorescence, possibly be-
cause of quenching by the heme group of HRP).
Enzyme activity assay and recycling of fibrils
Chimeric fibrils were washed twice with buffer and recovered by
centrifugation. Ure2193-AP fibrils (600 mL, ~30 mm) were allowed to
react with pNPP (20 mL, 500 mm) for 10 min before recovery by
centrifugation at 10000g for 10 min. The recovered fibrils were
then washed with buffer A four times to ensure the complete re-
moval of product, before beginning a new round of reaction with
pNPP. The recycling was performed four times, and the mass and
activity of the fibrils were measured at each round.
After reaction with ABTS, the Ure2180-HRP fibrils became purple
and could not be washed back to their original color. These prod-
uct-bound fibrils showed a significant loss of activity. Therefore,
3,3’,5,5’-tetramethylbenzidine (TMB), which did not show irreversi-
ble binding to fibrils, was used instead as the substrate. Ure2180-
HRP fibrils (500 mL, ~25 mm) were reacted with TMB (10 mL) for
10 min and recycled by centrifugation. The recycled Ure2180-HRP
fibrils were then washed with buffer B once to remove products
and reacted with TMB again. The recycling was performed four
times. The Ure2180-HRP fibril mass and activity were monitored by
BCA assay and ABTS, respectively, at each round of recycling.
To measure the steady-state kinetic parameters, WT AP was diluted
to 0.005 mm and soluble and fibrillar Ure2193-AP were diluted to
0.05 mm and reacted with pNPP (New England BioLabs) in the
range of 3.125–1000 mm. Dynamic light scattering measurements
confirmed that fibrillar Ure2193-AP remained aggregated after dilu-
tion to 0.05 mm and incubation for 4 h. Product formation was
monitored by absorbance at 405 nm for 10 min. For reactions with
HRP-containing constructs, the ABTS was in the range 31.25–
1500 mm. The protein concentrations used were as follows: WT
HRP, soluble Ure2180-HRP, and soluble Ure2193-HRP 0.03 mm ; fibril-
lar Ure2180-HRP and fibrillar Ure2193-HRP 0.06 mm. The peroxide
concentration in all HRP assays was 2 mm. Product formation was
monitored by absorbance at 405 nm for 5 min, and the initial rates
of reaction were determined. The final specific activity of WT HRP
was very similar to that reported previously.[15]
Microcolumn assay
The microcolumn device was constructed using soft lithography
techniques.[20,24] The device was fabricated in polydimethylsiloxane
(PDMS; Dow Corning) using SU8 on silicon masters and plasma-
bonded on a glass slide to seal the device. The size of the column
was 5 mm  1 mm  0.02 mm to give a calculated volume of less
than 0.1 mL. One end of the column was blocked with 1% agarose
introduced as a solution at 100 8C into half of the device and left
to cool in situ to form a gel; the other end was left open. The
Ure2193-AP and Ure2180-HRP fibrils were washed with buffer and
diluted to around 15 mm, then the fibrils were injected and trapped
into the column from the open side. The interface of the blocking
agarose and stacking of the enzymatic fibrils were observed by
light microscopy. ThT (20 mm) was pumped into the column for ap-
proximately 10 min, then excess ThT was washed out by pumping
buffer through the column. The fluorescence of the trapped fibrils
was monitored by fluorescence microscopy before and after load-
ing with ThT. After first washing with buffer A, the colorless sub-
strate pNPP (500 mm) was introduced into the Ure2193-AP micro-
column with a syringe pump, and the yellow product was collect-
ed from the outlet. After running pNPP, the Ure2193-AP microcol-
umn was washed with buffer A to remove any substrate or
product. The fluorescent substrate 2’-(2-benzothiazoyl)-6’-hydroxy-
benzothiazole phosphate (BBTP, AttoPhos AP fluorescent Substrate
System, Promega), was then pumped into the washed Ure2193-AP
microcolumn, and the bright yellow product was collected. No
cross reaction was detected between pNPP (or its product) and
BBTP. The Ure2180-HRP microcolumn was first washed with buffer
B and then the substrate 10-acetyl-3,7-dihydroxyphenoxazine
(ADHP, QuantaRed Enhanced Chemifluorescent HRP Substrate,
Thermo) was pumped in, and the bright pink product was
collected.
Blue/white selection assay
The gene fragment Ure2193-HRP fused with BamH I sites at the
two termini (B-UH-B) was amplified by polymerase chain reaction
(PCR). The pUC19 plasmid (ThermoScientific) contains an ampicillin
resistance gene and the lacZ gene, which encodes b-galactosidase,
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and contains a BamH I site. The plasmid pHSG299 (Takara) is similar
to pUC19 except that it has kanamycin resistance. The B-UH-B
gene and pUC19 and pHSG299 plasmids were cut with BamH I for
3 h at 30 8C and extracted from agarose gel. The linear pUC19 was
treated with SAP (1000 units/mL, used at 1 mL enzyme per 10 mL of
plasmid) or Ure2193-AP fibrils (around 50 mm, 1 mL fibrils per 10 mL
of plasmid) for 1 h at 37 8C. Samples that contained SAP were incu-
bated at 70 8C for 30 min to inactivate the SAP; samples that had
been treated with Ure2193-AP fibrils instead of SAP were not sub-
jected to this treatment, but the Ure2193-AP fibrils were removed
by centrifugation at 12000g for 10 min and recycled. The recy-
cled Ure2193-AP fibrils were washed twice with deionized water
and used to treat the linear pUC19 and pHSG299 plasmids for 1 h
at 37 8C, then the plasmids were separated from Ure2193-AP fibrils
by centrifugation at 12000g for 10 min. All SAP- and Ure2193-AP
fibril-treated plasmids were ligated to the B-UH-B gene (also cut
with BamH I) by T4 ligase for 12 h at 16 8C. As controls, linear
pUC19 and pHSG299 were treated with buffer instead of SAP or
Ure2193-AP before ligation with the gene fragments. All ligation
products were transformed into Top10 cells and spread on 2YT
plates coated with IPTG and 5-bromo-4-chloro-3-indolyl-b-d-galac-
topyranoside (X-Gal). After approximately 14 h incubation at 37 8C,
the plates were photographed and the blue (negative) colonies
and white (positive) colonies were counted by using Image J
software.
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